The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
Publications
Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances.
Seminars in respiratory and critical care medicine. 2003;24(4):445-54
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-1997. A 60-year-old man with pulmonary infiltrates after a bone marrow transplantation.
The New England journal of medicine. 1997;337(7):480-9
Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.
Cancer. 1971;27(5):1074-80
Busulphan lung.
Thorax. 1968;23(2):187-93
Busulfan lung. Report of two cases and review of the literature.
The American journal of roentgenology, radium therapy, and nuclear medicine. 1974;120(1):151-6
Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy.
Cancer. 1968;22(5):1027-32